Advertisement

Topics

Clinical Trials About "0035 Placebo Syndromes" RSS

12:54 EST 19th November 2018 | BioPortfolio

We list hundreds of Clinical Trials about "0035 Placebo Syndromes" on BioPortfolio. We draw our references from global clinical trials data listed on ClinicalTrials.gov and refresh our database daily.

More Information about "0035 Placebo Syndromes" on BioPortfolio

We have published hundreds of 0035 Placebo Syndromes news stories on BioPortfolio along with dozens of 0035 Placebo Syndromes Clinical Trials and PubMed Articles about 0035 Placebo Syndromes for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of 0035 Placebo Syndromes Companies in our database. You can also find out about relevant 0035 Placebo Syndromes Drugs and Medications on this site too.

Showing "0035 Placebo Syndromes" Clinical Trials 1–25 of 19,000+

Extremely Relevant

A Study to Assess the Safety and Effectiveness of SJP-0035 for the Treatment of Patients With Dry Eye Disease

A double-masked, randomized, multi-center, placebo-controlled, parallel-group study in adult patients with Dry Eye Disease (DED). Patients will be randomly assigned to receive either SJP-0035 0.001% or placebo


Safety and Efficacy of SJP-0035 Ophthalmic Solution in Patients With Moderate to Severe Corneal Epithelial Disorders

The purpose of this study is to determine whether SJP-0035 ophthalmic solution is effective in promoting corneal epithelial wound healing in conditions associated with corneal epithelial disorders.

Safety and Efficacy Study of SJP-0035 Ophthalmic Solution in Patients With Moderate to Severe Corneal Epithelial Disorders

The purpose of the study is to determine if SJP-0035 ophthalmic solution is effective in promoting corneal epithelial wound healing in conditions associated with corneal epithelial disorders.


Relevant

Phase 2 Study of KLS-0611 in Patients With Dry Eye Syndromes

To evaluate the efficacy and safety of KLS-0611 compared to placebo in patients with dry eye syndromes.

Myelodysplastic Syndromes (MDS) Event Free Survival With Iron Chelation Therapy Study

The primary purpose of this study is to prospectively assess the efficacy and safety of iron chelation therapy with deferasirox compared to placebo in patients with myelodysplastic syndromes (low/int-1 risk) and transfusional iron overload.

Yan Nian Jiu Zhuan Fa Improve Chronic Fatigue Syndromes

This study is to disclose the mechanism of characteristic Tao yin exercises regulate Chronic Fatigue Syndromes based on Brain-Gut Axis.Explore the clinical manifestation of Chronic Fatigue Syndromes, changes of neurotransmitter and central brain function. Then provide some new methods of treating Chronic Fatigue Syndromes.

Incidence of Geriatric Syndromes Overlap

The overlap of depression and delirium as geriatric syndromes present in elderly patients with hospital admission due to hip fracture has been previously studied. Nevertheless, the relationships between these two clinical processes and other geriatric syndromes, especially malnutrition, have not been studied. For this reason, a prospective cohort study has been designed to know the differences in the incidence of geriatric syndromes during hospital admission due to hip fracture...

Lenalidomide Versus Placebo in Myelodysplastic Syndromes With a Deletion 5q- Abnormality

Patients are randomised to one of two treatment groups or to placebo and take treatment for 16 weeks. At this timepoint patients are evaluated for response, and if not responding they are entered into open label treatment with active drug. All responders continue in double blind treatment for 52 weeks, and if still responding then move to open label treatment for a further two years. All responders may stay in the study for three years.

Effect of rHDL on Atherosclerosis - Safety and Efficacy: THE ERASE TRIAL

Currently available therapies to treat Acute Coronary Syndromes(ACS) have several limitations including; the relatively long treatment duration required before apparent significant benefit; the inability to achieve reversal of the atherosclerotic process; and poor patient compliance due to chronicity of therapy. This study will assess the effects of rHDL compared with placebo on indices of atherosclerosis progression and regression as assessed with intravascular ultrasound (IVU...

A Study of Luspatercept (ACE-536) to Treat Anemia Due to Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes

The study will be conducted in compliance with the International Council on Harmonisation (ICH) of Technical Requirements for Registration of Pharmaceuticals for Human Use/Good Clinical Practice (GCP) and applicable regulatory requirements. This is a Phase 3, double-blind, randomized, placebo-controlled, multicenter study to determine the efficacy and safety of luspatercept (ACE-536) versus placebo in subjects with anemia due to International Prognostic Scoring System-Revised ...

Prospective Study of Molecular Predictors of Survival in Myelodysplastic Syndromes

This study aims at prospectively enrolling a cohort of 400 incident cases of myelodysplastic syndromes (MDS) at diagnosis, to evaluate the impact of recurrent mutations on overall survival and event-free survival, using next generation sequencing. Patients are affected by ineffective hematopoiesis and a propensity to leukemia in the elderly with a global incidence of 10/100,000/year.

Combination of 5-Azacitidine and Lenalidomide in Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML) Myelodysplastic Syndromes

The hypothesis of this study is that 5-aza and lenalidomide act synergistically in MDS and AML patients with chromosomal abnormalities involving monosomy 5 or del5q. Therefore, this phase I study will investigate the maximum tolerated dose (MTD) of lenalidomide in combination with a fixed dose of 5-aza in this patient population.

Effects of the Ivabradine on Reduction of Inflammatory Markers in Patients With Acute Coronary Syndrome

The purpose of this study is to investigate whether a pure heart rate-lowering agent (Ivabradine) reduces vascular inflammatory stress in patients with acute coronary syndromes

A Study to Access the Safety/Efficacy of Thalidomide in the Treatment of Anemia in Patients With Myelodysplastic Syndromes

The primary objective of the study is to determine the efficacy of thalidomide for the treatment of anemia in patients with myelodysplastic syndromes (MDS).

A Study of Aerobic Exercise for Adolescents With Subthreshold Mood Syndromes

This study will investigate the effects of aerobic exercise on mental states, cognition, and long-term outcomes in adolescents with subthreshold depressive and/or hypomanic syndromes and in non-clinical school children

iCare 2: Personalized Genomic Mutation Informed Treatment of Patients With Myelodysplastic Syndromes

This open-label, randomized, parallel group phase II study will investigate the efficacy of computational biology-informed treatment vs. standard of care treatment for patients with relapsed or refractory myelodysplastic syndromes (MDS).

Decitabine and Tretinoin in Treating Patients With Myelodysplastic Syndromes

RATIONALE: Drugs used in chemotherapy, such as decitabine, work in different ways to stop the growth of myelodysplastic cells, either by killing the cells or by stopping them from dividing. Tretinoin and decitabine may help myelodysplastic cells become more like normal cells, and to grow and spread more slowly. Giving decitabine together with tretinoin may be an effective treatment for myelodysplastic syndromes. PURPOSE: This phase I/II trial is studying the side effects and b...

Treatment of the Anemia of Myelodysplastic Syndromes by the Association of Epoetin Beta and All Trans Retinoic Acid

The purpose of this study is - To evaluate the efficacy of association of Erythropoetin (Neorecormon) and ATRA in patients with low risk myelodysplastic syndromes - To evaluate the tolerance of this treatment

Metoclopramide in Treating Patients With Anemia Due to Myelodysplastic Syndromes

RATIONALE: Metoclopramide may cause the body to make more red blood cells. It may treat anemia due to myelodysplastic syndromes. PURPOSE: This phase II trial is studying how well metoclopramide works in treating patients with anemia due to myelodysplastic syndromes.

Amifampridine Phosphate for the Treatment of Pediatric Congenital Myasthenic Syndromes

This randomized, double-blind, controlled, outpatient two-period, two-treatment crossover study is designed to evaluate the efficacy and safety of amifampridine phosphate in patients (ages 2 to 17) diagnosed with certain genetic subtypes of CMS and demonstrated open label (amifampridine phosphate) or history of sustained amifampridine benefit from treatment.

PXD101 in Treating Patients With Myelodysplastic Syndromes

RATIONALE: PXD101 may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the cancer. PURPOSE: This phase II trial is studying how well PXD101 works in treating patients with myelodysplastic syndromes.

Safety & Pharmacokinetics of Pegolsihematide for Treatment of Anemia Patient With Myelodysplastic Syndromes

The primary objectives of the trial are to assess the safety and pharmacokinetics profile of pegolsihematide for treatment of anemia patient with myelodysplastic syndromes.

Calcitriol and Dexamethasone in Patients With Myelodysplastic Syndromes

This is a study to determine the response rate in patients with myelodysplastic syndromes treated with calcitriol and dexamethasone.

An Extention Study of Safety of Canakinumab in Japanese Patients With Periodic Fever Syndromes

The primary objective of this study is to evaluate safety and tolerability of ACZ885 in this extension study. This extension study offers the opportunity for patients who completed Epoch 4 of the preceding CACZ885N2301 study to continue to be treated with ACZ885 until approval in Japan of the drug in Periodic Fever Syndromes or until development of ACZ885 in Periodic Fever Syndromes is suspended.

Bortezomib and Low Dose Cytarabine in the Treatment of High-Risk Myelodysplastic Syndromes

We are evaluating the efficacy of the association of Low dose Cytarabine in association with Bortezomib in the treatment of patients diagnosed with high risk Myelodysplastic syndromes. Our aim is to decrease transfusion requirements and if possible induce a complete or at least a partial remission.


More From BioPortfolio on "0035 Placebo Syndromes"

Advertisement
Quick Search
Advertisement
Advertisement